NCT07312318 AI-Driven Dynamic Prediction of Non-Target Lesion Progression After PCI: A Chinese Multicenter Cohort Study
| NCT ID | NCT07312318 |
| Status | Recruiting |
| Phase | — |
| Sponsor | China-Japan Friendship Hospital |
| Condition | Coronary Heart Disease (CHD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 12,000 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 12,000 participants in total. It began in 2025-09-01 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Coronary artery disease remains a leading cause of global mortality. Although percutaneous coronary intervention (PCI) improves patient outcomes, the long-term risk of major adverse cardiovascular events (MACE) driven by the progression of non-target lesions (NTLs) remains substantial and continues to increase, while current risk stratification tools remain inadequate for predicting NTL progression. This multicenter cohort study aims to develop an artificial intelligence (AI)-driven system for the dynamic prediction and precision stratification of NTL progression after PCI. Utilizing comprehensive multimodal data from 52,577 Chinese patients-including clinical profiles, multi-omics blood biomarkers, and coronary imaging-the research pursues three primary objectives: (1) to identify and validate 2-3 specific biomarkers for NTL progression risk using multi-omics approaches; (2) to construct an integrated risk assessment and early-warning system by applying machine learning to multimodal data for predicting NTL progression and MACE; and (3) to establish metabolic and imaging-based subtypes to create a precision management system that optimizes secondary prevention strategies by identifying specific high-risk populations. This study is expected to provide a novel tool for accurate identification of high-risk patients and personalized post-PCI management, ultimately aiming to improve long-term prognosis.
Eligibility Criteria
Inclusion Criteria: 1. Aged 18 years or older; 2. Scheduled for or having undergone PCI; 3. Baseline plasma sample obtainable; 4. Informed consent obtained Exclusion Criteria: 1. Pregnancy or lactation; 2. Severe hepatic or renal dysfunction; 3. Active autoimmune disease; 4. Missing critical data
Contact & Investigator
Fang Wang
PRINCIPAL INVESTIGATOR
China-Japan Friendship Hospital
Frequently Asked Questions
Who can join the NCT07312318 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Heart Disease (CHD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07312318 currently recruiting?
Yes, NCT07312318 is actively recruiting participants. Contact the research team at wangfang@cjfh.org.cn for enrollment information.
Where is the NCT07312318 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07312318 clinical trial?
NCT07312318 is sponsored by China-Japan Friendship Hospital. The principal investigator is Fang Wang at China-Japan Friendship Hospital. The trial plans to enroll 12,000 participants.